modelC09AA09

Diagram of C09AA09

Extends from Pharmacokinetic.Models.PK_1C_enteral.

Information

name:Fosinopril
ATC code:C09AA09
route:oral
compartments:1
dosage:20mg
volume of distribution:28.6L
clearance:19.1L/h
other parameters in model implementation

Fosinopril is an angiotensin-converting enzyme (ACE) inhibitor indicated for the treatment of hypertension and heart failure. It is a prodrug that is converted to its active form, fosinoprilat, in the liver. Fosinopril is approved and widely used in current clinical practice.

Pharmacokinetics

Pharmacokinetic parameters reported for healthy adult volunteers following a single oral dose.

References

  1. Ding, PY, et al., & Liao, WC (1999). Fosinopril: pharmacokinetics and pharmacodynamics in Chinese subjects. Journal of clinical pharmacology 39(2) 155–160. DOI:10.1177/00912709922007705 PUBMED:https://pubmed.ncbi.nlm.nih.gov/11563407

  2. Ding, PY, et al., & Liao, W (2000). Does Chinese ethnicity affect the pharmacokinetics and pharmacodynamics of angiotensin-converting enzyme inhibitors?. Journal of human hypertension 14(3) 163–170. DOI:10.1038/sj.jhh.1000856 PUBMED:https://pubmed.ncbi.nlm.nih.gov/10694829

  3. Hu, OY, et al., & Chu, KM (1997). Pharmacokinetics of fosinoprilat in Chinese and whites after intravenous administration. Journal of clinical pharmacology 37(9) 834–840. DOI:10.1002/j.1552-4604.1997.tb05632.x PUBMED:https://pubmed.ncbi.nlm.nih.gov/9549638

Parameters

TypeNameDefaultDescription
Modelica.Units.SI.Massweight (from PK_1C)75patient weight (kg)
Modelica.Units.SI.SpecificVolumeVdPerKg (from PK_1C)0.9Volume of distribution (L/kg)
Modelica.Units.SI.MassFractionF (from PK_1C)0.8bioavailiability (0-1)
Pharmacolibrary.Types.ClearanceCl (from PK_1C)20clearance
Modelica.Units.SI.TimeadminTime (from PK_1C)60first administration time (s)
Modelica.Units.SI.TimeadminDuration (from PK_1C)600administration duration (s)
Modelica.Units.SI.TimeadminPeriod (from PK_1C)8*60*60period of administration (default 8 hours)(s)
Pharmacolibrary.Types.MassadminMass (from PK_1C)1000administration mass (mg)
IntegeradminCount (from PK_1C)8number of dose administered (1)
Pharmacolibrary.Types.VolumeVd (from PK_1C)VdPerKg*weightVolume of distribution (m3)
Pharmacolibrary.Types.MassConcentrationCmin (from PK_1C)0.004minimal therapeutic range
Pharmacolibrary.Types.MassConcentrationCmax (from PK_1C)0.008minimal therapeutic range
Pharmacolibrary.Types.MassConcentrationCtox_peak (from PK_1C)0.012toxicity peak level
Pharmacolibrary.Types.MassConcentrationCtox_trough (from PK_1C)0.006toxicity trough level
Pharmacolibrary.Types.TransferRateka (from PK_1C_enteral)0.016666666666666666first order absorption rate
Modelica.Units.SI.TimeTlag (from PK_1C_enteral)600delay between oral administration and absorption (default 10min)

Connectors

TypeNameDefaultDescription
Types.ConcentrationOutputC_central (from PK_1C)
Interfaces.ConcentrationPort_bcentralCPort (from PK_1C)

Components

TypeNameDefaultDescription
Pharmacokinetic.NoPerfusedTissueCompartmentcentral (from PK_1C)
Pharmacokinetic.ClearanceDrivenEliminationelim (from PK_1C)
Sources.PeriodicDoseperiodicDose (from PK_1C)
Modelica.Units.SI.Timet1_2 (from PK_1C)elimination half-life

Revisions

  • 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)